---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-25-000128"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:35:11.478333+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q3 revenue up 14% to $131.9M, raises FY guidance; adjusted EBITDA margin 30%

## Summary
- Total revenue $131.9M (+14% YoY); testing rev $127.8M (+17%); GAAP net income $19.1M.
- Decipher revenue $82.2M (+26%); Afirma $43.2M (+7%); total testing volume +19% to 43,679.
- Adjusted EBITDA $39.7M (30% margin); cash from ops $44.8M; cash & equivalents $366.4M.
- Raised FY2025 total revenue guidance to $506-510M; testing rev guidance $484-487M (+16%).
- Completed enrollment of Percepta Nasal Swab NIGHTINGALE trial; upcoming TrueMRD and Prosigna LDT launches.

## SEC filing metadata
- accession: 0001384101-25-000128
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410125000128/0001384101-25-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410125000128/vcyt-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-25-000128
- JSON: https://secwatch.observer/filing/0001384101-25-000128.json
- Plain text: https://secwatch.observer/filing/0001384101-25-000128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.